EDMONTON, ALBERTA--(MARKET WIRE)--Jun 22, 2006 -- ViRexx Medical Corp. (TSX:VIR.TO - News) (AMEX:REX - News), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that enrollment has been completed in its licensing partner, Unither Pharmaceutical’s, Phase III trials for OvaRex® MAb for patients with stage III/IV advanced ovarian cancer who have successfully completed front-line therapy. The second of two identical Phase III trials, IMPACT II, achieved its targeted enrollment of 177 patients earlier this week. The first trial, IMPACT I, met its enrollment target in December of 2005.
